LEO Lymphoma Study Participants

Dr. Cerhan's Lymphoma Epidemiology Lab is enrolling participants for its Lymphoma Epidemiology of Outcomes (LEO) cohort study for non-Hodgkin's lymphoma.

Study goals

The LEO lymphoma study is a five-year minimally invasive observational study to track patient care and quality of life. Dr. Cerhan's research team collects informational data and biologic samples from study participants to help understand the causes of different types of non-Hodgkin's lymphoma, the best treatments and the best ways to help survivors.

The goals of the LEO lymphoma study are to:

  • Follow patients over time to identify factors that affect prognosis and survivorship of non-Hodgkin's lymphoma
  • Improve diagnosis, risk stratification, treatment, and short- and long-term management of patients with non-Hodgkin's lymphoma
  • Find new and better ways to improve the length and quality of life of people living with non-Hodgkin's lymphoma
  • Create a long-term cohort registry of non-Hodgkin's lymphoma patients
  • Create a bank of blood and tissue specimens

The LEO lymphoma study supports a broad research agenda aimed at identifying factors that significantly influence prognosis and survivorship, including:

  • Diet and lifestyle
  • Environmental and chemical exposure
  • Medical history
  • Family history of cancer
  • Treatment status and effects
  • Physical, social, emotional and functional well-being

Eligibility and procedures

Study participants must complete questionnaires, give a one-time blood sample, allow review of diagnostic biopsy material, and permit study staff to review medical records.

Patients are eligible if they have been diagnosed with lymphoma within six months of enrollment and are actively being seen by a hematology provider at Mayo Clinic or being treated at a participating center, including:

  • Emory University or Grady Health System
  • Mayo Clinic
  • MD Anderson Cancer Center
  • The University of Iowa
  • University of Miami or Jackson Memorial Hospital
  • University of Rochester Medical Center
  • Washington University
  • Weill Cornell Medical Center

Frequently asked questions

How will the LEO study benefit me?

While there is no direct benefit to you for participating in the LEO lymphoma study, data from the study helps researchers gain a better understanding of disorders of the blood and lymphatic systems.

The Mayo Clinic research team ultimately hopes to discover innovative methods to improve patient care and quality of life for people with lymphoma.

How long is the study?

The study tracks each participant for 36 months from date of enrollment. Data analysis is ongoing. The study is funded through May 31, 2020.

How is my confidentiality protected?

Only the LEO lymphoma study personnel at Mayo Clinic know your identity, and each participating center can only view its own participants' information. Your identity isn't shared with any researcher outside the study. Information learned about you through this study doesn't become part of your medical record.

I'm not getting treatment for my diagnosis. Can I still participate?

Yes. Participants must have been diagnosed within six months of enrollment to be eligible for participation in the LEO lymphoma study. Patients are eligible to participate regardless of their treatment status.

Is there a charge to participate?

No, participation in the study is free.

Will participating in the LEO study affect my cancer treatment?

No. Participation in the LEO study will not affect your cancer treatment or your medical care in any way.


For information about the Mayo Clinic LEO lymphoma study, contact Dr. Cerhan's team at 800-610-7093 (toll-free) or by email at lymphoma@mayo.edu.

Visit ClinicalTrials.gov to learn more about the Lymphoma Epidemiology of Outcomes cohort study.